Content area
Full Text
Tofacitinib reduces medical costs and the risk of job loss in patients with rheumatoid arthritis (RA), according to findings of a Pfizer-sponsored post hoc analysis published in Rheumatology.
Investigators analysed data from two phase III trials in a total of 1115 patients with RA and inadequate response to methotrexate (MTX) or tumour necrosis factor inhibitors (TNFi), who were randomised to treatment with tofacitinib 5 or 10 mg twice...